A brief overview of the pathophysiology, diagnosis, and treatment of heparin-induced thrombocytopenia (HIT) is discussed. Following any exposure to unfractionated heparin or low-molecular-weight ...

Thrombocytopenia Thrombocytopenia is a condition denoted by a low number of blood platelets. Given that these blood platelets ...

A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

The FDA has accepted the sNDA for avatrombopag for the treatment of thrombocytopenia in pediatric patients aged 1 year and ...

Thrombocytopenia may be inherited (could manifest as a feature of hereditary syndromes) or acquired (could be medication-induced or due to conditions such as leukemia or sepsis) Thrombocytopenia ...

Heparin-Induced Thrombocytopenia (HIT) is a life-threatening complication following heparin exposure. The webinar presentation will discuss the pathogenesis, incidence, clinical and laboratory ...

Rilzabrutinib improved efficacy and QOL outcomes among pre-treated adult patients with immune thrombocytopenia.

Common types of blood disorders include anemia, where there is a deficiency of red blood cells or hemoglobin, leading to fatigue and weakness, and thrombocytopenia, characterized by low platelet ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune thrombocytopenia (ITP) in the adult population, met its primary endpoint.

Source Reference: Kuter DJ "Efficacy and safety of oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3 ...

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...